Latest & greatest articles for Aspartate Aminotransferase

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Aspartate Aminotransferase or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Aspartate Aminotransferase and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Aspartate Aminotransferase

1. Hepatitis C Virus Clearance by Direct-acting Antiviral Results in Rapid Resolution of Hepatocytic Injury as Indicated by Both Alanine Aminotransferase and Aspartate Aminotransferase Normalization (Full text)

Hepatitis C Virus Clearance by Direct-acting Antiviral Results in Rapid Resolution of Hepatocytic Injury as Indicated by Both Alanine Aminotransferase and Aspartate Aminotransferase Normalization Background and Aims: Hepatitis C virus (HCV) infection results in hepatocytic injury with elevation of both alanine aminotransferase (ALT) and aspartate aminotransferase (AST). It remains to be determined if direct-acting antiviral treatment can terminate hepatocytic injury following virologic response

2018 Journal of clinical and translational hepatology

2. Diagnostic Accuracy of Aspartate Aminotransferase to Platelet Ratio Index and Fibrosis 4 Scores in Predicting Advanced Liver Fibrosis in Patients with End-stage Renal Disease and Chronic Viral Hepatitis: Experience from Pakistan (Full text)

Diagnostic Accuracy of Aspartate Aminotransferase to Platelet Ratio Index and Fibrosis 4 Scores in Predicting Advanced Liver Fibrosis in Patients with End-stage Renal Disease and Chronic Viral Hepatitis: Experience from Pakistan The aim was to assess the diagnostic accuracy of APRI and FIB-4 in assessing the stage of liver fibrosis in end stage renal disease (ESRD) patients with chronic viral hepatitis and to compare the two tests with standard tru-cut liver biopsy.The study was conducted (...) %) patients had both infections. The mean Ishak fibrosis score was 1.95 ± 2. Advanced fibrosis was noted in 37 (34%) patients. Univariate analysis showed that advanced liver fibrosis was associated with lower platelets counts (P=0.001) and higher aspartate aminotransferase (AST) (P=0.001), alanine aminotransferase (ALT) (P=0.022), APRI score (P=0.001) and FIB-4 score (P=0.001). On logistic regression analysis, only APRI score (P < 0.001) was found to be the independent variable associated with advanced

2018 Journal of translational internal medicine

3. Transient elastography versus aspartate aminotransferase to platelet ratio index for the assessment of liver fibrosis in patients with hepatitis C: systematic review and meta-analysis

Transient elastography versus aspartate aminotransferase to platelet ratio index for the assessment of liver fibrosis in patients with hepatitis C: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2015 PROSPERO

4. Appropriateness phase 1 OHTAC recommendations: Annual health exams, aspartate aminotransferase testing, chloride testing, creatine kinase testing, ferritin testing, folate testing, and vitamin B12 testing

Appropriateness phase 1 OHTAC recommendations: Annual health exams, aspartate aminotransferase testing, chloride testing, creatine kinase testing, ferritin testing, folate testing, and vitamin B12 testing Appropriateness phase 1 OHTAC recommendations: annual health exams, aspartate aminotransferase testing, chloride testing, creatine kinase testing, ferritin testing, folate testing, and vitamin B12 testing Appropriateness phase 1 OHTAC recommendations: annual health exams, aspartate (...) , aspartate aminotransferase testing, chloride testing, creatine kinase testing, ferritin testing, folate testing, and vitamin B12 testing. Toronto: Health Quality Ontario (HQO). OHTAC recommendation. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Health Services Misuse; Health Services Needs and Demand; Humans; Methods Language Published English Country of organisation Canada Province or state Ontario English summary An English language summary is available. Address

2014 Health Technology Assessment (HTA) Database.